	US 11,753,409 B2
	Crystalline salts of a B-RAF kinase inhibitor
Ulrike Werthmann, Ingelheim am Rhein (DE); Gerd-Michael Maier, Ingelheim am Rhein (DE); Bodo Betzemeier, Ingelheim am Rhein (DE); and Otmar Schaaf, Ingelheim am Rhein (DE)
Assigned to Xynomic Pharmaceuticals, Inc., Dover, DE (US)
Filed by Xynomic Pharmaceuticals, Inc., Dover, DE (US)
Filed on Mar. 11, 2022, as Appl. No. 17/692,695.
Application 17/692,695 is a continuation of application No. 16/759,187, granted, now 11,306,086, previously published as PCT/US2018/057792, filed on Oct. 26, 2018.
Claims priority of provisional application 62/577,313, filed on Oct. 26, 2017.
Prior Publication US 2022/0204506 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01)

CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)]

16 Claims

1. A method of treating a cancer in a patient, comprising administering to the patient a therapeutically effective amount of crystalline N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide monosuccinate salt having an X-ray powder diffraction pattern comprising at least one of the following peaks, in terms of 2θ: 15.4° ±0.5°, 20.0° ±0.5°, and 21.8° ±0.5°, wherein the cancer is an intestinal cancer.